ArticleFrontiers in neurology
The association of ApoB/ApoA-I ratio with intracranial atherosclerotic stenosis in young patients with ischemic stroke.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, the incidence of ischemic stroke among young adults has increased significantly. Identifying risk factors associated with ischemic stroke in this demographic is crucial for effective prevention. This study aimed to investigate the relationship of the serum apolipoprotein B (ApoB)/apolipoprotein A-I (ApoA-I) ratio with intracranial atherosclerotic stenosis (ICAS) in young patients with ischemic stroke. We collected data from patients with ischemic stroke aged 18 to 45 years. ICAS was assessed using computed tomography angiography (CTA), and serum levels of total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, ApoA-I, and ApoB were measured. The ApoB/ApoA-I ratio was subsequently calculated. Demographic and clinical characteristics were compared between the ICAS group and the non-ICASs group. Multivariate logistic regression analysis was employed to identify independent risk factors for ICAS in young ischemic stroke patients. A total of 161 young ischemic stroke patients were included, with 89 in the ICAS group and 72 in the non-ICAS group. In a univariate analysis, patients with ICAS had a higher prevalence of diabetes mellitus, smoking, and hyperlipidemia, as well as higher levels of ApoB and a higher ApoB/ApoA-I ratio, but lower levels of HDL-C and ApoA-I compared to those without ICAS. After adjustment for age, sex, smoking, hypertension, diabetes mellitus, and HDL-C, multivariable analyses indicated that ICAS had a dose-response relationship with apoB/apoAI ratio quartiles: the second quartile, OR, 3.051 (95% CI, 1.185 to 7.855); the third quartile, 3.516 (1.504 to 8.219); and the fourth quartile, 4.743 (2.109 to 10.667), when referenced to the first quartile. Our study showed that a higher apoB/apoAI ratio is independently associated with ICAS in young stroke patients, after careful exclusion of alternative arteriopathies and adjustment for confounders. However, findings should be confirmed with vessel wall imaging in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.